BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 25, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/22 cls
Acorda (ACOR) Banc of America Securities William Ho Upgrade Buy (from neutral) -5% $17.46
Fortis Patrick Moriarty New Buy
Ho maintained a $26 target but upgraded the stock because the shares have fallen "considerably" over recent months.
Moriarty set a $33 target. He thinks ACOR's Fampridine-SR, a sustained-release formulation of 4-aminopyridine (4-AP) to treat multiple sclerosis (MS), will reach sales of $314M by 2012.
Actelion (SWX:ATLN) C.E. Unterberg, Towbin Andrew Fein Downgrade Underperform (from market perform) -1% CHF56.50
Fein said the approval of Letairis ambrisentan from Gilead (GILD) for pulmonary arterial hypertension (PAH) "will represent the beginning of the unwinding" of ATLN's PAH drug Tracleer.
Ark (LSE:AKT) Jefferies Robin Campbell New Buy 1% 139p
Campbell set a 200p target. He thinks AKT's Cerepro (EG009)...

Read the full 873 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >